US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Monkeypox Concept

1,685.78

-5.8430-0.35%

Number of Gainers:6

Number of Losers:3

Number of Flat:2

PE:- -

High:1,701.25

Open:1,691.93

Low:1,680.58

Close:1,691.62

Volume:23.15M

Turnover:996.81M

Market Cap:187.70B

Float Cap:187.18B

Loading ...

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

THOMSON REUTERS

Viatris Inc. to Participate in Upcoming Healthcare Investor Conferences

Tonix Pharmaceuticals receives IND clearance for Phase 2 study of TNX-102 SL

Tonix Pharmaceuticals Announces FDA Ind Clearance for Phase 2 Study of Tnx-102 Sl for the Treatment of Major Depressive Disorder

THOMSON REUTERS

Tonix Pharmaceuticals - Plans to Initiate Study Enrollment in Mid-2026

THOMSON REUTERS

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Quest Diagnostics (DGX) Gets a Hold from Barclays

Sprint Bioscience Ab - Agreement Includes USD 14 Mln Upfront and up to USD 400 Mln in Milestones

THOMSON REUTERS

Sprint Bioscience Ab - Sells Trex1 Cancer Program to Gilead

THOMSON REUTERS

BRIEF-Tonix Pharmaceuticals - Amends Sales Agreement With Alliance Global Partners - SEC Filing

Tonix Pharmaceuticals - Increases Offering Price to $400 Mln - SEC Filing

THOMSON REUTERS

Press Release: Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

BRIEF-Aspen Neuroscience announces $115 million Series C financing to accelerate personalized cell therapy programs

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

THOMSON REUTERS

Aspen Neuroscience: Series C Round Co-Led by Orbimed, Arch Venture Partners & Others, Participation From S32, Axon Ventures, Kite & Others

THOMSON REUTERS

Quest Diagnostics (DGX) Receives a Buy from Mizuho Securities

Viatris Study Finds Falling Antibiotic Prices Amid Rising Production Costs

Inovio Pharmaceuticals Q3 EPS USD -0.87

Gilead In Oct, Reached Settlement With A Tax Authority Related To A Prior Year Legal Entity Restructuring - Filing

Gilead Provides Update on Phase 3 ASCENT-07 Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1685.7805,"timestamp":1764709199999,"preClose":1691.6235,"halted":0,"volume":23147846,"delay":0,"changeRate":-0.003454,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-5.843018,"latestTime":"12-02 16:00:00 EST","open":1691.9335,"high":1701.25,"low":1680.5822,"amount":996813779.573888,"amplitude":0.012218,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1764752400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.237261,"peRate":36.090635,"turnoverRate":0.008575,"increases":6,"decrements":3,"flats":1,"marketCap":187700986591,"floatMarketCap":187178272808.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1701.25,"amplitude":0.012218,"preClose":1691.6235,"low":1680.5822,"pbRate":"4.237261","latestPrice":1685.7805,"volume":23147846,"delay":0,"open":1691.9335,"prevYearClose":1284.7982,"prevWeekClose":1713.9587,"prevMonthClose":1713.9587,"prevQuarterClose":1540.8464,"fiveDayClose":1707.4333,"twentyDayClose":1659.6542,"sixtyDayClose":1583.7096,"secType":"PLATE","market":"US","turnoverRate":0.008575,"peRate":36.090635,"marketCap":187700986591,"floatMarketCap":187178272808.875,"timestamp":1764709199999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":6,"down":3,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2585467379","title":"Gilead Foundation Commits Over $3 Million to Address Food Insecurity","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585467379?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:30","pubTimestamp":1763991000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUAYQJFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","LU0823416689.USD","GILD","LU0058720904.USD","BK4532","LU1839511570.USD","LU2468319806.SGD","BK4139","IE0002270589.USD","BK4568","SG9999015945.SGD","IE00B3T34201.USD","IE00BKVL7J92.USD","BK4588","SG9999015978.USD","LU2087621335.USD","BK4566","LU2089984988.USD","LU0234570918.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","SG9999015952.SGD","LU1674673691.USD","LU0114720955.EUR","BK4550","BK4585","LU1066053197.SGD","LU1430594728.SGD","BK4578","IE00B19Z3581.USD","LU0889565916.HKD","LU2324357040.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU1585245621.USD","SG9999015986.USD","LU0320765992.SGD","LU1674673428.USD","LU0109394709.USD","LU1066051498.USD","BK4583","LU1778281490.HKD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2585462580","title":"Viatris Inc. to Participate in Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462580","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462580?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:01","pubTimestamp":1763989272,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3bVV94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1839511570.USD","EVR","LU2087621335.USD","BK4585","PIPR","BK4127","BK4007","VTRS","BK4583"],"gpt_icon":0},{"id":"2585614044","title":"Tonix Pharmaceuticals receives IND clearance for Phase 2 study of TNX-102 SL","url":"https://stock-news.laohu8.com/highlight/detail?id=2585614044","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585614044?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:15","pubTimestamp":1763986559,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceutical announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application to support clinical devel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-receives-ind-clearance-for-phase-2-study-of-tnx-102-sl-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-receives-ind-clearance-for-phase-2-study-of-tnx-102-sl-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNXP","IND","BK4139","BK4583"],"gpt_icon":0},{"id":"2585646135","title":"Tonix Pharmaceuticals Announces FDA Ind Clearance for Phase 2 Study of Tnx-102 Sl for the Treatment of Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2585646135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585646135?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUACG970G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"2585546136","title":"Tonix Pharmaceuticals - Plans to Initiate Study Enrollment in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2585546136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585546136?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUACG970G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4583","TNXP"],"gpt_icon":0},{"id":"2585934461","title":"Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2585934461","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585934461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193346/28908/en/Tonix-Pharmaceuticals-Announces-FDA-IND-Clearance-for-Phase-2-Study-of-TNX-102-SL-for-the-Treatment-of-Major-Depressive-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU0128526141.USD","BK4139","BK4135","BK4161","LU0029874061.USD","LU2360032135.SGD","TAT","HI","CNS","LU2125154778.USD","TNXP","IND","LU2125154935.USD"],"gpt_icon":0},{"id":"2585457858","title":"Quest Diagnostics (DGX) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585457858","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585457858?lang=en_us&edition=fundamental","pubTime":"2025-11-24 16:45","pubTimestamp":1763973943,"startTime":"0","endTime":"0","summary":"In a report released today, Luke Sergott from Barclays maintained a Hold rating on Quest Diagnostics, with a price target of $195.00. Sergott cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/quest-diagnostics-dgx-gets-a-hold-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/quest-diagnostics-dgx-gets-a-hold-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4588","DGX","LU0950375773.USD","LU2506951958.HKD","LU2506951875.HKD","LU2506952097.USD","BK4585","BK4567","LU0823417737.USD","LU0823417653.USD","LU1854104046.USD","LU2506952170.USD","BK4196","LU1854103824.USD"],"gpt_icon":0},{"id":"2585458690","title":"Sprint Bioscience Ab - Agreement Includes USD 14 Mln Upfront and up to USD 400 Mln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2585458690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585458690?lang=en_us&edition=fundamental","pubTime":"2025-11-24 13:08","pubTimestamp":1763960926,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3WX155:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","LU2087621335.USD","IE00B3T34201.USD","BK4568","IE00BSNM7G36.USD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU0289739699.SGD","LU2468319806.SGD","IE00B19Z3581.USD","BK4550","BK4578","BK4566","IE00B19Z3B42.SGD","LU2089984988.USD","LU0114720955.EUR","LU1571399168.USD","IE00BKVL7J92.USD","LU0823416689.USD","BK4139","SG9999015952.SGD","LU0889565916.HKD","BK4585","LU1066053197.SGD","LU1674673691.USD","BK4583","LU1839511570.USD","LU1066051498.USD","LU0234570918.USD","BK4532","SG9999015978.USD","LU1778281490.HKD","IE00B7SZLL34.SGD","SG9999015945.SGD","LU1430594728.SGD","LU1674673428.USD","IE0002270589.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","LU0882574055.USD","LU1585245621.USD","GILD","LU0058720904.USD"],"gpt_icon":0},{"id":"2585145869","title":"Sprint Bioscience Ab - Sells Trex1 Cancer Program to Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145869?lang=en_us&edition=fundamental","pubTime":"2025-11-24 13:08","pubTimestamp":1763960926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3WX155:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","BK4566","SG9999015945.SGD","IE00B19Z3B42.SGD","BK4139","LU0889565916.HKD","LU0234570918.USD","LU0109394709.USD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","BK4578","LU1778281490.HKD","LU0320765992.SGD","LU1674673428.USD","BK4585","IE00BKVL7J92.USD","BK4550","BK4583","BK4532","LU1585245621.USD","LU1066051498.USD","IE0002270589.USD","GILD","LU2087621335.USD","LU0289739699.SGD","LU0882574055.USD","LU1430594728.SGD","LU1066053197.SGD","LU1839511570.USD","IE00B19Z3581.USD","LU0114720955.EUR","SG9999015978.USD","LU2089984988.USD","SG9999015986.USD","BK4588","BK4568","IE00B3T34201.USD","LU0058720904.USD","LU1571399168.USD","LU2468319806.SGD","SG9999015952.SGD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU1674673691.USD"],"gpt_icon":0},{"id":"2585296941","title":"BRIEF-Tonix Pharmaceuticals - Amends Sales Agreement With Alliance Global Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585296941","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585296941?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:01","pubTimestamp":1763762470,"startTime":"0","endTime":"0","summary":"BRIEF-Tonix Pharmaceuticals - Amends Sales Agreement With Alliance Global Partners - SEC FilingNov 21  - Tonix Pharmaceuticals Holding Corp TNXP.O:TONIX PHARMACEUTICALS - AMENDS SALES AGREEMENT WITH ALLIANCE GLOBAL PARTNERS - SEC FILINGTONIX PHARMACEUTICALS - INCREASES OFFERING PRICE TO $400 MILLION - SEC FILINGFurther company coverage: TNXP.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX13W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4583","BK4139"],"gpt_icon":0},{"id":"2585129885","title":"Tonix Pharmaceuticals - Increases Offering Price to $400 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585129885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585129885?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:51","pubTimestamp":1763761908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX13W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"2584139148","title":"Press Release: Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2584139148","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584139148?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:30","pubTimestamp":1763641800,"startTime":"0","endTime":"0","summary":"-- Sol-Gel intends to pursue high-frequency BCC as an additional indication. for its lead drug candidate SGT-610, which, if approved, could at least. -- In September 2025, Sol-Gel announced Health Canada approval of EPSOLAY. -- Sol-Gel signed an additional agreement with Viatris covering Australia. NESS ZIONA, Israel, Nov. 20, 2025  -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the third quarter ending September 30, 2025, and provided a corporate update.-- Sol-Gel's ongoing Phase 3 clinical trial of SGT-610 . for Gorlin syndrome, for which top-line results are expected in the. fourth quarter of 2026, has led to growing physician interest in its. potential use in patients with severe, high-frequency basal cell. devastating form of high-frequency BCC, was found to have a lesion. harboring a PTCH-1 mutation, and Sol-Gel agreed to provide SGT-610 for. compassionate use. S","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","SLGL","BK4588","BK4007","BK4567","VTRS","BK4583","BK4104","BCC","AVAX.USD.HKCC","BK4585","SOL.USD.HKCC","LU2087621335.USD"],"gpt_icon":0},{"id":"2584398151","title":"BRIEF-Aspen Neuroscience announces $115 million Series C financing to accelerate personalized cell therapy programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584398151","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584398151?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:16","pubTimestamp":1763641011,"startTime":"0","endTime":"0","summary":"BRIEF-Aspen Neuroscience announces $115 million Series C financing to accelerate personalized cell therapy programsNov 20  - Gilead Sciences Inc GILD.O:ASPEN NEUROSCIENCE ANNOUNCES $115 MILLION SERIES C FINANCING TO ACCELERATE PERSONALIZED CELL THERAPY PROGRAMSASPEN NEUROSCIENCE: SERIES C ROUND CO-LED BY ORBIMED, ARCH VENTURE PARTNERS & OTHERS, PARTICIPATION FROM S32, AXON VENTURES, KITE & OTHERSSource text: nPn3H4ZmTaFurther company coverage: GILD.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA95J3GP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4578","LU2089984988.USD","LU1674673428.USD","LU1674673691.USD","BK4566","SG9999015986.USD","LU1839511570.USD","LU0289739699.SGD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU1430594728.SGD","IE00B19Z3581.USD","BK4139","LU2087621335.USD","BK4588","BK4568","IE00B3T34201.USD","BK4550","IE00BSNM7G36.USD","LU1778281490.HKD","IE0002270589.USD","LU0109394709.USD","BK4585","SG9999015952.SGD","LU0889565916.HKD","LU0234570918.USD","LU2468319806.SGD","BK4532","LU2324357040.USD","IE00B7SZLL34.SGD","LU1585245621.USD","SG9999015978.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0320765992.SGD","GILD","LU0058720904.USD","BK4583","LU1066051498.USD","LU1571399168.USD","LU0114720955.EUR","LU0882574055.USD"],"gpt_icon":0},{"id":"2584139854","title":"Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584139854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584139854?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:13","pubTimestamp":1763640789,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA95J3GP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","LU0889565916.HKD","LU1674673428.USD","BK4578","IE00BKVL7J92.USD","LU2089984988.USD","SG9999015986.USD","IE00B7SZLL34.SGD","LU1571399168.USD","SG9999015978.USD","LU1674673691.USD","BK4588","LU1778281490.HKD","LU0109394709.USD","BK4585","IE00BZ1G4Q59.USD","LU1066051498.USD","BK4550","BK4532","IE00B19Z3B42.SGD","LU0823416689.USD","LU1839511570.USD","SG9999015945.SGD","LU0320765992.SGD","LU2087621335.USD","IE00B3T34201.USD","LU2468319806.SGD","GILD","LU0114720955.EUR","BK4566","LU0882574055.USD","LU2324357040.USD","LU0058720904.USD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4568","BK4139","LU0234570918.USD","SG9999015952.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU1585245621.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2584113981","title":"Aspen Neuroscience: Series C Round Co-Led by Orbimed, Arch Venture Partners & Others, Participation From S32, Axon Ventures, Kite & Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2584113981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584113981?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:13","pubTimestamp":1763640789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA95J3GP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z3581.USD","LU1778281490.HKD","LU1674673691.USD","LU1585245621.USD","GILD","BK4583","IE00B19Z3B42.SGD","BK4585","LU2468319806.SGD","BK4568","IE00B3T34201.USD","LU1066051498.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU0234570918.USD","LU0823416689.USD","SG9999015978.USD","LU1430594728.SGD","LU1066053197.SGD","BK4139","BK4550","LU1839511570.USD","LU1674673428.USD","BK4532","LU0320765992.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4578","LU0058720904.USD","IE00BZ1G4Q59.USD","SG9999015986.USD","LU0882574055.USD","SG9999015952.SGD","IE0002270589.USD","LU0114720955.EUR","BK4588","LU0109394709.USD","LU0889565916.HKD","LU1571399168.USD","BK4566","LU2087621335.USD","LU2089984988.USD","LU2324357040.USD","SG9999015945.SGD"],"gpt_icon":0},{"id":"2584186331","title":"Quest Diagnostics (DGX) Receives a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2584186331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584186331?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:55","pubTimestamp":1763625329,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Ann Hynes reiterated a Buy rating on Quest Diagnostics yesterday. The company’s shares closed yesterday at $185.96. Hynes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/quest-diagnostics-dgx-receives-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/quest-diagnostics-dgx-receives-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4567","MFG","LU0950375773.USD","LU1854103824.USD","BK4585","LU0823417653.USD","LU2506951958.HKD","BK4588","LU0823417737.USD","LU1854104046.USD","BK4196","LU2506951875.HKD","DGX","BK4207","LU2506952097.USD","BK4583","LU2506952170.USD"],"gpt_icon":0},{"id":"2584197222","title":"Viatris Study Finds Falling Antibiotic Prices Amid Rising Production Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584197222","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584197222?lang=en_us&edition=fundamental","pubTime":"2025-11-20 08:15","pubTimestamp":1763597738,"startTime":"0","endTime":"0","summary":"Viatris Inc., in collaboration with Medicines for Europe, has published the results of an independent study analyzing the off-patent medicines market in Europe, with a particular focus on antibiotics. The study found that between 2020 and 2024, the average price of the ten most widely used off-patent antibiotics dropped by 10.4%, despite significant increases in production costs and inflation. The analysis highlights the growing challenge of ensuring patient access to essential medicines amid price pressures and supply shortages. Viatris and Medicines for Europe are urging policymakers and healthcare leaders to reform national pricing and procurement systems to safeguard the availability of vital antibiotics and strengthen sustainable access to off-patent medicines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL7mx5Dq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","BK4585","BK4583","LU1839511570.USD","VTRS","BK4007","BK4588"],"gpt_icon":0},{"id":"2584921646","title":"Inovio Pharmaceuticals Q3 EPS USD -0.87","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921646","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921646?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:15","pubTimestamp":1763572543,"startTime":"0","endTime":"0","summary":"Nov 10 (Reuters) - Inovio Pharmaceuticals Q3 net income USD -45.5 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 10-NOV-202521:05:48.363 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6C5VL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4568","BK4139","INO"],"gpt_icon":0},{"id":"2584921892","title":"Gilead In Oct, Reached Settlement With A Tax Authority Related To A Prior Year Legal Entity Restructuring - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921892?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:07","pubTimestamp":1763572056,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc ::*GILEAD: IN OCT, REACHED SETTLEMENT WITH A TAX AUTHORITY RELATED TO A PRIOR YEAR LEGAL ENTITY RESTRUCTURING - FILING*GILEAD: SEES $450 MILLION OF INCOME TAX BENEFIT AND A CORRESP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDb84JKf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU1839511570.USD","BK4532","SG9999015952.SGD","SG9999015945.SGD","LU1674673691.USD","BK4566","IE00BZ1G4Q59.USD","LU2089984988.USD","BK4578","SG9999015986.USD","IE00B19Z3581.USD","LU0114720955.EUR","LU2468319806.SGD","LU0882574055.USD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0289739699.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","BK4139","LU2087621335.USD","LU1430594728.SGD","LU1674673428.USD","GILD","LU1066051498.USD","LU1066053197.SGD","LU0234570918.USD","BK4588","BK4585","LU1571399168.USD","LU2324357040.USD","BK4550","LU0823416689.USD","BK4583","BK4568","IE00B3T34201.USD","LU1778281490.HKD","LU0109394709.USD","IE00B7SZLL34.SGD","LU0058720904.USD","SG9999015978.USD","LU1585245621.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2584929755","title":"Gilead Provides Update on Phase 3 ASCENT-07 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929755","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929755?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:06","pubTimestamp":1763571986,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Gilead Sciences Inc ::*GILEAD PROVIDES UPDATE ON PHASE 3 ASCENT-07 STUDY*GILEAD: PHASE 3 ASCENT-07 STUDY DID NOT MEET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL*GILEAD: SAFETY PRO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDc7CXn7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0882574055.USD","BK4532","SG9999015986.USD","BK4550","LU0823416689.USD","LU2087621335.USD","IE00B3T34201.USD","LU0058720904.USD","IE00B7SZLL34.SGD","BK4139","GILD","LU0889565916.HKD","LU0234570918.USD","LU1674673428.USD","LU0109394709.USD","BK4588","LU1066051498.USD","SG9999015952.SGD","BK4568","IE00BSNM7G36.USD","LU0289739699.SGD","LU2089984988.USD","LU1066053197.SGD","SG9999015978.USD","IE0002270589.USD","LU1585245621.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4566","LU1778281490.HKD","LU1430594728.SGD","LU2324357040.USD","LU0114720955.EUR","IE00BKVL7J92.USD","BK4585","LU1674673691.USD","SG9999015945.SGD","IE00B19Z3581.USD","BK4583","LU1571399168.USD","IE00B19Z3B42.SGD","LU1839511570.USD","BK4578"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}]}}